SEONGNAM, South Korea, Jan. 19, 2020 /PRNewswire/ -- Bridge Biotherapeutics Inc., a clinical stage biotech company headquartered in Seongnam, Republic of Korea, announced that the Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration (FDA) has been...
from PR Newswire: https://ift.tt/38nLdXv
No comments:
Post a Comment